In a B16 murine melanoma model, it was demonstrated that increased production of infiltrating CD45+, CD8+ T, and tumor-specific CD8+ T cells, and depleting CD8+ T cells completely abolished the therapeutic effects [95]. This evidence concerns the gene CD8A and melanoma.